Heterologous MVA-S prime Ad5-S boost regimen induces high and persistent levels of neutralizing antibody response against SARS coronavirus
Identifieur interne : 003988 ( Main/Exploration ); précédent : 003987; suivant : 003989Heterologous MVA-S prime Ad5-S boost regimen induces high and persistent levels of neutralizing antibody response against SARS coronavirus
Auteurs : Lei Ba [États-Unis] ; Christopher E. Yi [États-Unis] ; Linqi Zhang [États-Unis] ; David D. Ho [États-Unis] ; Zhiwei Chen [États-Unis]Source :
- Applied Microbiology and Biotechnology [ 0175-7598 ] ; 2007-10-01.
Descripteurs français
- KwdFr :
- Adénovirus humains (génétique), Adénovirus humains (immunologie), Animaux, Anticorps antiviraux (sang), Femelle, Glycoprotéine de spicule des coronavirus, Glycoprotéines membranaires (génétique), Glycoprotéines membranaires (immunologie), Glycoprotéines membranaires (métabolisme), Immunisation, Lapins, Protéines de l'enveloppe virale (génétique), Protéines de l'enveloppe virale (immunologie), Protéines de l'enveloppe virale (métabolisme), Rappel de vaccin, Souris, Souris de lignée BALB C, Syndrome respiratoire aigu sévère (), Syndrome respiratoire aigu sévère (immunologie), Syndrome respiratoire aigu sévère (virologie), Tests de neutralisation, Vaccins antiviraux (administration et posologie), Vaccins antiviraux (génétique), Vaccins antiviraux (immunologie), Vaccins à ADN (administration et posologie), Vaccins à ADN (immunologie), Virus de la vaccine (génétique), Virus de la vaccine (immunologie), Virus du SRAS (immunologie).
- Wicri :
- topic : Vaccin.
- MESH :
- administration et posologie : Vaccins antiviraux, Vaccins à ADN.
- génétique : Adénovirus humains, Glycoprotéines membranaires, Protéines de l'enveloppe virale, Vaccins antiviraux, Virus de la vaccine.
- immunologie : Adénovirus humains, Glycoprotéines membranaires, Protéines de l'enveloppe virale, Syndrome respiratoire aigu sévère, Vaccins antiviraux, Vaccins à ADN, Virus de la vaccine, Virus du SRAS.
- métabolisme : Glycoprotéines membranaires, Protéines de l'enveloppe virale.
- sang : Anticorps antiviraux.
- virologie : Syndrome respiratoire aigu sévère.
- Animaux, Femelle, Glycoprotéine de spicule des coronavirus, Immunisation, Lapins, Rappel de vaccin, Souris, Souris de lignée BALB C, Syndrome respiratoire aigu sévère, Tests de neutralisation.
English descriptors
- KwdEn :
- Ad5, Adenoviruses, Human (genetics), Adenoviruses, Human (immunology), Animals, Antibodies, Viral (blood), Female, Immunization, Immunization, Secondary, MVA, Membrane Glycoproteins (genetics), Membrane Glycoproteins (immunology), Membrane Glycoproteins (metabolism), Mice, Mice, Inbred BALB C, Neutralization Tests, Rabbits, SARS, SARS Virus (immunology), SARS-CoV, Severe Acute Respiratory Syndrome (immunology), Severe Acute Respiratory Syndrome (prevention & control), Severe Acute Respiratory Syndrome (virology), Spike Glycoprotein, Coronavirus, Vaccine, Vaccines, DNA (administration & dosage), Vaccines, DNA (immunology), Vaccinia virus (genetics), Vaccinia virus (immunology), Viral Envelope Proteins (genetics), Viral Envelope Proteins (immunology), Viral Envelope Proteins (metabolism), Viral Vaccines (administration & dosage), Viral Vaccines (genetics), Viral Vaccines (immunology).
- MESH :
- chemical , administration & dosage : Vaccines, DNA, Viral Vaccines.
- chemical , blood : Antibodies, Viral.
- chemical , metabolism : Membrane Glycoproteins, Viral Envelope Proteins.
- genetics : Adenoviruses, Human, Membrane Glycoproteins, Vaccinia virus, Viral Envelope Proteins, Viral Vaccines.
- immunology : Adenoviruses, Human, Membrane Glycoproteins, SARS Virus, Severe Acute Respiratory Syndrome, Vaccines, DNA, Vaccinia virus, Viral Envelope Proteins, Viral Vaccines.
- prevention & control : Severe Acute Respiratory Syndrome.
- virology : Severe Acute Respiratory Syndrome.
- Animals, Female, Immunization, Immunization, Secondary, Mice, Mice, Inbred BALB C, Neutralization Tests, Rabbits, Spike Glycoprotein, Coronavirus.
Abstract
Abstract: Severe acute respiratory syndrome (SARS) is caused by a novel coronavirus (CoV), SARS-CoV. In previous studies, we showed that a SARS-CoV spike (S) glycoprotein-based modified vaccinia Ankara (MVA-S) vaccine could induce strong neutralizing antibody (Nab) response which might have played a critical role in protecting Chinese rhesus monkeys from the pathogenic viral challenge. To date, however, it remains unknown what the minimal level of Nab is required to achieve sterile immunity in humans. It is therefore important to explore techniques to maximize the level of Nab response in vivo. Here, we evaluate various vaccination regimens using combinations of DNA-S, MVA-S, and adenovirus type 5 (Ad5-S) vaccines. We show that in vaccinated mice and rabbits, a heterologous MVA-S prime with Ad5-S boost regimen induces the highest and most persistent level of Nab response when compared with other combinations. Interestingly, the initial level of Nab after prime does not necessarily predict the magnitude of the secondary response after the boost. Thus, our data provides a promising optimal regimen for vaccine development in humans against SARS-CoV infection.
Url:
- https://api.istex.fr/ark:/67375/VQC-445KHZNC-2/fulltext.pdf
- http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7079952
DOI: 10.1007/s00253-007-1073-y
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000154
- to stream Istex, to step Curation: 000154
- to stream Istex, to step Checkpoint: 001332
- to stream Pmc, to step Corpus: 000264
- to stream Pmc, to step Curation: 000264
- to stream Pmc, to step Checkpoint: 000F56
- to stream PubMed, to step Corpus: 001D81
- to stream PubMed, to step Curation: 001D81
- to stream PubMed, to step Checkpoint: 001D96
- to stream Ncbi, to step Merge: 001A03
- to stream Ncbi, to step Curation: 001A03
- to stream Ncbi, to step Checkpoint: 001A03
- to stream Main, to step Merge: 003B43
- to stream Main, to step Curation: 003988
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Heterologous MVA-S prime Ad5-S boost regimen induces high and persistent levels of neutralizing antibody response against SARS coronavirus</title><author><name sortKey="Ba, Lei" sort="Ba, Lei" uniqKey="Ba L" first="Lei" last="Ba">Lei Ba</name></author><author><name sortKey="Yi, Christopher E" sort="Yi, Christopher E" uniqKey="Yi C" first="Christopher E." last="Yi">Christopher E. Yi</name></author><author><name sortKey="Zhang, Linqi" sort="Zhang, Linqi" uniqKey="Zhang L" first="Linqi" last="Zhang">Linqi Zhang</name></author><author><name sortKey="Ho, David D" sort="Ho, David D" uniqKey="Ho D" first="David D." last="Ho">David D. Ho</name></author><author><name sortKey="Chen, Zhiwei" sort="Chen, Zhiwei" uniqKey="Chen Z" first="Zhiwei" last="Chen">Zhiwei Chen</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:A96ED13487FF996AE72E7D4D4C505BA5394832D9</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1007/s00253-007-1073-y</idno><idno type="url">https://api.istex.fr/ark:/67375/VQC-445KHZNC-2/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000154</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000154</idno><idno type="wicri:Area/Istex/Curation">000154</idno><idno type="wicri:Area/Istex/Checkpoint">001332</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001332</idno><idno type="wicri:doubleKey">0175-7598:2007:Ba L:heterologous:mva:s</idno><idno type="wicri:source">PMC</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7079952</idno><idno type="RBID">PMC:7079952</idno><idno type="wicri:Area/Pmc/Corpus">000264</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000264</idno><idno type="wicri:Area/Pmc/Curation">000264</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000264</idno><idno type="wicri:Area/Pmc/Checkpoint">000F56</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000F56</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:17581748</idno><idno type="wicri:Area/PubMed/Corpus">001D81</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001D81</idno><idno type="wicri:Area/PubMed/Curation">001D81</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001D81</idno><idno type="wicri:Area/PubMed/Checkpoint">001D96</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001D96</idno><idno type="wicri:Area/Ncbi/Merge">001A03</idno><idno type="wicri:Area/Ncbi/Curation">001A03</idno><idno type="wicri:Area/Ncbi/Checkpoint">001A03</idno><idno type="wicri:doubleKey">0175-7598:2007:Ba L:heterologous:mva:s</idno><idno type="wicri:Area/Main/Merge">003B43</idno><idno type="wicri:Area/Main/Curation">003988</idno><idno type="wicri:Area/Main/Exploration">003988</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Heterologous MVA-S prime Ad5-S boost regimen induces high and persistent levels of neutralizing antibody response against SARS coronavirus</title><author><name sortKey="Ba, Lei" sort="Ba, Lei" uniqKey="Ba L" first="Lei" last="Ba">Lei Ba</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Aaron Diamond AIDS Research Center, The Rockefeller University, 455 1st Avenue, 10016, New York, NY</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Yi, Christopher E" sort="Yi, Christopher E" uniqKey="Yi C" first="Christopher E." last="Yi">Christopher E. Yi</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Aaron Diamond AIDS Research Center, The Rockefeller University, 455 1st Avenue, 10016, New York, NY</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Zhang, Linqi" sort="Zhang, Linqi" uniqKey="Zhang L" first="Linqi" last="Zhang">Linqi Zhang</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Aaron Diamond AIDS Research Center, The Rockefeller University, 455 1st Avenue, 10016, New York, NY</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Ho, David D" sort="Ho, David D" uniqKey="Ho D" first="David D." last="Ho">David D. Ho</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Aaron Diamond AIDS Research Center, The Rockefeller University, 455 1st Avenue, 10016, New York, NY</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Chen, Zhiwei" sort="Chen, Zhiwei" uniqKey="Chen Z" first="Zhiwei" last="Chen">Zhiwei Chen</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Aaron Diamond AIDS Research Center, The Rockefeller University, 455 1st Avenue, 10016, New York, NY</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation><affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Applied Microbiology and Biotechnology</title><title level="j" type="abbrev">Appl Microbiol Biotechnol</title><idno type="ISSN">0175-7598</idno><idno type="eISSN">1432-0614</idno><imprint><publisher>Springer-Verlag</publisher><pubPlace>Berlin/Heidelberg</pubPlace><date type="published" when="2007-10-01">2007-10-01</date><biblScope unit="volume">76</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="1131">1131</biblScope><biblScope unit="page" to="1136">1136</biblScope></imprint><idno type="ISSN">0175-7598</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0175-7598</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Ad5</term><term>Adenoviruses, Human (genetics)</term><term>Adenoviruses, Human (immunology)</term><term>Animals</term><term>Antibodies, Viral (blood)</term><term>Female</term><term>Immunization</term><term>Immunization, Secondary</term><term>MVA</term><term>Membrane Glycoproteins (genetics)</term><term>Membrane Glycoproteins (immunology)</term><term>Membrane Glycoproteins (metabolism)</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Neutralization Tests</term><term>Rabbits</term><term>SARS</term><term>SARS Virus (immunology)</term><term>SARS-CoV</term><term>Severe Acute Respiratory Syndrome (immunology)</term><term>Severe Acute Respiratory Syndrome (prevention & control)</term><term>Severe Acute Respiratory Syndrome (virology)</term><term>Spike Glycoprotein, Coronavirus</term><term>Vaccine</term><term>Vaccines, DNA (administration & dosage)</term><term>Vaccines, DNA (immunology)</term><term>Vaccinia virus (genetics)</term><term>Vaccinia virus (immunology)</term><term>Viral Envelope Proteins (genetics)</term><term>Viral Envelope Proteins (immunology)</term><term>Viral Envelope Proteins (metabolism)</term><term>Viral Vaccines (administration & dosage)</term><term>Viral Vaccines (genetics)</term><term>Viral Vaccines (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adénovirus humains (génétique)</term><term>Adénovirus humains (immunologie)</term><term>Animaux</term><term>Anticorps antiviraux (sang)</term><term>Femelle</term><term>Glycoprotéine de spicule des coronavirus</term><term>Glycoprotéines membranaires (génétique)</term><term>Glycoprotéines membranaires (immunologie)</term><term>Glycoprotéines membranaires (métabolisme)</term><term>Immunisation</term><term>Lapins</term><term>Protéines de l'enveloppe virale (génétique)</term><term>Protéines de l'enveloppe virale (immunologie)</term><term>Protéines de l'enveloppe virale (métabolisme)</term><term>Rappel de vaccin</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Syndrome respiratoire aigu sévère ()</term><term>Syndrome respiratoire aigu sévère (immunologie)</term><term>Syndrome respiratoire aigu sévère (virologie)</term><term>Tests de neutralisation</term><term>Vaccins antiviraux (administration et posologie)</term><term>Vaccins antiviraux (génétique)</term><term>Vaccins antiviraux (immunologie)</term><term>Vaccins à ADN (administration et posologie)</term><term>Vaccins à ADN (immunologie)</term><term>Virus de la vaccine (génétique)</term><term>Virus de la vaccine (immunologie)</term><term>Virus du SRAS (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Vaccines, DNA</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Membrane Glycoproteins</term><term>Viral Envelope Proteins</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Vaccin</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antiviraux</term><term>Vaccins à ADN</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Adenoviruses, Human</term><term>Membrane Glycoproteins</term><term>Vaccinia virus</term><term>Viral Envelope Proteins</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Adénovirus humains</term><term>Glycoprotéines membranaires</term><term>Protéines de l'enveloppe virale</term><term>Vaccins antiviraux</term><term>Virus de la vaccine</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Adénovirus humains</term><term>Glycoprotéines membranaires</term><term>Protéines de l'enveloppe virale</term><term>Syndrome respiratoire aigu sévère</term><term>Vaccins antiviraux</term><term>Vaccins à ADN</term><term>Virus de la vaccine</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Adenoviruses, Human</term><term>Membrane Glycoproteins</term><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome</term><term>Vaccines, DNA</term><term>Vaccinia virus</term><term>Viral Envelope Proteins</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Glycoprotéines membranaires</term><term>Protéines de l'enveloppe virale</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Female</term><term>Immunization</term><term>Immunization, Secondary</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Neutralization Tests</term><term>Rabbits</term><term>Spike Glycoprotein, Coronavirus</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Femelle</term><term>Glycoprotéine de spicule des coronavirus</term><term>Immunisation</term><term>Lapins</term><term>Rappel de vaccin</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Syndrome respiratoire aigu sévère</term><term>Tests de neutralisation</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Severe acute respiratory syndrome (SARS) is caused by a novel coronavirus (CoV), SARS-CoV. In previous studies, we showed that a SARS-CoV spike (S) glycoprotein-based modified vaccinia Ankara (MVA-S) vaccine could induce strong neutralizing antibody (Nab) response which might have played a critical role in protecting Chinese rhesus monkeys from the pathogenic viral challenge. To date, however, it remains unknown what the minimal level of Nab is required to achieve sterile immunity in humans. It is therefore important to explore techniques to maximize the level of Nab response in vivo. Here, we evaluate various vaccination regimens using combinations of DNA-S, MVA-S, and adenovirus type 5 (Ad5-S) vaccines. We show that in vaccinated mice and rabbits, a heterologous MVA-S prime with Ad5-S boost regimen induces the highest and most persistent level of Nab response when compared with other combinations. Interestingly, the initial level of Nab after prime does not necessarily predict the magnitude of the secondary response after the boost. Thus, our data provides a promising optimal regimen for vaccine development in humans against SARS-CoV infection.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>État de New York</li></region></list><tree><country name="États-Unis"><region name="État de New York"><name sortKey="Ba, Lei" sort="Ba, Lei" uniqKey="Ba L" first="Lei" last="Ba">Lei Ba</name></region><name sortKey="Chen, Zhiwei" sort="Chen, Zhiwei" uniqKey="Chen Z" first="Zhiwei" last="Chen">Zhiwei Chen</name><name sortKey="Ho, David D" sort="Ho, David D" uniqKey="Ho D" first="David D." last="Ho">David D. Ho</name><name sortKey="Yi, Christopher E" sort="Yi, Christopher E" uniqKey="Yi C" first="Christopher E." last="Yi">Christopher E. Yi</name><name sortKey="Zhang, Linqi" sort="Zhang, Linqi" uniqKey="Zhang L" first="Linqi" last="Zhang">Linqi Zhang</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003988 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003988 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:A96ED13487FF996AE72E7D4D4C505BA5394832D9
|texte= Heterologous MVA-S prime Ad5-S boost regimen induces high and persistent levels of neutralizing antibody response against SARS coronavirus
}}
| This area was generated with Dilib version V0.6.33. |  |